JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rush, R. S.
Right arrow Articles by Faulkner, G. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rush, R. S.
Right arrow Articles by Faulkner, G. D.

Inhibition of two monomeric butyrylcholinesterases from rabbit liver by chlorpromazine and other drugs

RS Rush, AR Main, BF Kilpatrick and GD Faulkner

A new form of cholinesterases has been discovered in rabbit liver; the new enzymes are monomeric butyrylcholinesterases (EC 3.1.1.8), mBuChE I and mBuChE II. These enzymes are inhibited reversibly by chlorpromazine in the pharmacologically active concentration range and they exhibit mixed competitive-noncompetitive inhibition patterns. The apparent competitive inhibition constants, Ki with chlorpromazine, are 1.8 x 10(- 6) M for mBuChE I and 7.6 x 10(-6) M for mBuChE II, whereas the noncompetitive inhibition constant is 1.1 x 10(-5) M for mBuChE II as determined by spectrophotometric assay with n-butyrylthiocholine iodide substrate. Although inhibition of mBuChE I also exhibited noncompetitive behavior, a binding constant could not be determined. Human serum oligometric butyrylcholinesterase (oBuChE) was employed as a control cholinesterase and also demonstrated mixed inhibition kinetics. The competitive inhibition constant for the oBuChE was 5.5 x 10(-7) M in the low substrate region, whereas the apparent noncompetitive binding constant was 1.6 x 10(-5) M in the activated higher substrate region with n-butyrylthiocholine iodide as the substrate and chlorpromazine as the reversible inhibitor. The presence of a noncompetitive binding component indicates the presence of an operative modifier or allosteric site binding the inhibitor on both mBuChEs and the oBuChE. The inhibition constants were calculated assuming that the enzymes followed simple Michaelian kinetics.

Volume 216, Issue 3, pp. 586-591, 03/01/1981
Copyright © 1981 by American Society for Pharmacology and Experimental Therapeutics







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1981 by the American Society for Pharmacology and Experimental Therapeutics.